Linda Burkly - Mar 2, 2024 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, CHIEF SCIENTIFIC OFFICER
Signature
/s/ Linda C. Burkly
Stock symbol
EDIT
Transactions as of
Mar 2, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 08:03 PM
Previous filing
Jul 25, 2023
Next filing
Jul 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +24.8K +54.91% $0.00 70K Mar 2, 2024 Direct F1
transaction EDIT Common Stock Award $0 +15.1K +21.52% $0.00 85K Mar 2, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EDIT Stock Option (right to buy) Award $0 +74.4K $0.00 74.4K Mar 2, 2024 Common Stock 74.4K $10.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.
F2 Reflects the acquisition, upon the achievement of a specified business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 24, 2023. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on July 24, 2024, subject to continued service.
F3 This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.